Biotech Values

[DewDiligence]

Re: NVS-ENTA HCV program in GT2/3?

ENTA—This abstract suggests NVS may be moving forward with the HTA*/EDP-239 combination in GT2/GT3 patients.

Good find. Your hypothesis is consistent with the statement in NVS’ 2Q13 pipeline update that NVS was conducting a DDI study of DEB025 and another agent (#msg-90030018).

Note: My ENTA valuation model in #msg-92234861 ascribed only $100M to the NVS partnership, which may be unduly low.

*Host-Targeting Agent, i.e. DEB025.